Jason Bock, PhD, is a biotech executive known for building high-performing organizations that turn cutting-edge science into impactful biologic therapies. He joined MD Anderson in 2019 to launch the Biologics Development group, an internal biotech function created to advance MDACC-invented biologics toward the clinic. That initiative evolved into CTMC in May 2022, a joint venture between MD Anderson Cancer Center and Resilience, where he now serves as CEO.
CTMC was created to close the gap between academic discovery and industrial drug development, accelerating transformative cell therapies from concept to clinic. Operating out of a 60,000-square-foot cell therapy manufacturing facility in the Texas Medical Center, with 14 cleanrooms, process development and analytical labs, and teams located steps from MD Anderson, CTMC has already guided eight novel cell therapy programs through IND clearance.
Before founding CTMC, Jason served as Site Head and VP of Global CMC Biologics within Teva Pharmaceuticals’ Specialty R&D Division. Over more than a decade at Teva, the Biologics organization grew to 600+ employees, advanced 15 novel programs from preclinical to clinical development, and led three biologics through clinical development to global commercialization. He joined Teva through its acquisition of CoGenesys, a biotech spin-out from Human Genome Sciences (HGS), where he began his industry career.
Jason earned his BS in Biology from MIT and his PhD in Molecular and Cellular Physiology from Stanford University.